Latest & greatest articles for lung cancer

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on lung cancer or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on lung cancer and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for lung cancer

1101. Prophylactic cranial irradiation for preventing brain metastases in patients undergoing radical treatment for non-small cell lung cancer. (PubMed)

Prophylactic cranial irradiation for preventing brain metastases in patients undergoing radical treatment for non-small cell lung cancer. BACKGROUND: In non-small cell lung cancer (NSCLC), there is a relatively high incidence of brain metastases following radical treatment. At present, the role of prophylactic cranial irradiation (PCI) in this group of patients is not clear. OBJECTIVES: To investigate whether PCI has a role in the management of patients with NSCLC treated with radical intent (...) may reduce the incidence of brain metastases, but there is no evidence of a survival benefit. There is no evidence that any regimen is superior, and the effect of PCI on quality of life (QOL) is not known. AUTHORS' CONCLUSIONS: There is insufficient evidence to support the use of PCI in clinical practice. Where possible, patients should be offered entry into a clinical trial.

2005 Cochrane

1102. EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. (PubMed)

EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. Mutations of the epidermal growth factor receptor (EGFR) gene have been identified in specimens from patients with non-small-cell lung cancer who have a response to anilinoquinazoline EGFR inhibitors. Despite the dramatic responses to such inhibitors, most patients ultimately have a relapse. The mechanism of the drug resistance is unknown. Here we report the case of a patient with EGFR-mutant, gefitinib-responsive (...) , advanced non-small-cell lung cancer who had a relapse after two years of complete remission during treatment with gefitinib. The DNA sequence of the EGFR gene in his tumor biopsy specimen at relapse revealed the presence of a second point mutation, resulting in threonine-to-methionine amino acid change at position 790 of EGFR. Structural modeling and biochemical studies showed that this second mutation led to gefitinib resistance. Copyright 2005 Massachusetts Medical Society.

2005 NEJM

1103. Radon in homes and risk of lung cancer: collaborative analysis of individual data from 13 European case-control studies. (PubMed)

Radon in homes and risk of lung cancer: collaborative analysis of individual data from 13 European case-control studies. OBJECTIVE: To determine the risk of lung cancer associated with exposure at home to the radioactive disintegration products of naturally occurring radon gas. DESIGN: Collaborative analysis of individual data from 13 case-control studies of residential radon and lung cancer. SETTING: Nine European countries. SUBJECTS: 7148 cases of lung cancer and 14,208 controls. MAIN OUTCOME (...) MEASURES: Relative risks of lung cancer and radon gas concentrations in homes inhabited during the previous 5-34 years measured in becquerels (radon disintegrations per second) per cubic metre (Bq/m3) of household air. RESULTS: The mean measured radon concentration in homes of people in the control group was 97 Bq/m3, with 11% measuring > 200 and 4% measuring > 400 Bq/m3. For cases of lung cancer the mean concentration was 104 Bq/m3. The risk of lung cancer increased by 8.4% (95% confidence

Full Text available with Trip Pro

2005 BMJ

1105. The Role of Taxanes in First-line Therapy for Advanced Non-Small Cell Lung Cancer

The Role of Taxanes in First-line Therapy for Advanced Non-Small Cell Lung Cancer

2005 Cancer Care Ontario

1107. The Role of High Dose Rate Brachytherapy in the Palliation of Patients with Non-small Cell Lung Cancer

The Role of High Dose Rate Brachytherapy in the Palliation of Patients with Non-small Cell Lung Cancer

2005 Cancer Care Ontario

1108. The Role of Photodynamic Therapy (PDT) in Patients with Non-Small Cell Lung Cancer

The Role of Photodynamic Therapy (PDT) in Patients with Non-Small Cell Lung Cancer

2005 Cancer Care Ontario

1109. Vinorelbine plus cisplatin vs. observation in resected non-small-cell lung cancer. (PubMed)

Vinorelbine plus cisplatin vs. observation in resected non-small-cell lung cancer. 15972865 2005 06 23 2005 06 28 2013 11 21 1533-4406 352 25 2005 Jun 23 The New England journal of medicine N. Engl. J. Med. Vinorelbine plus cisplatin vs. observation in resected non-small-cell lung cancer. 2589-97 We undertook to determine whether adjuvant vinorelbine plus cisplatin prolongs overall survival among patients with completely resected early-stage non-small-cell lung cancer. We randomly assigned (...) patients with completely resected stage IB or stage II non-small-cell lung cancer to vinorelbine plus cisplatin or to observation. The primary end point was overall survival; principal secondary end points were recurrence-free survival and the toxicity and safety of the regimen. A total of 482 patients underwent randomization to vinorelbine plus cisplatin (242 patients) or observation (240); 45 percent of the patients had pathological stage IB disease and 55 percent had stage II, and all had an Eastern

2005 NEJM

1110. Erlotinib in lung cancer - molecular and clinical predictors of outcome. (PubMed)

Erlotinib in lung cancer - molecular and clinical predictors of outcome. 16014883 2005 07 14 2005 07 20 2015 11 19 1533-4406 353 2 2005 Jul 14 The New England journal of medicine N. Engl. J. Med. Erlotinib in lung cancer - molecular and clinical predictors of outcome. 133-44 A clinical trial that compared erlotinib with a placebo for non-small-cell lung cancer demonstrated a survival benefit for erlotinib. We used tumor-biopsy samples from participants in this trial to investigate whether (...) responsiveness to erlotinib and its impact on survival were associated with expression by the tumor of epidermal growth factor receptor (EGFR) and EGFR gene amplification and mutations. EGFR expression was evaluated immunohistochemically in non-small-cell lung cancer specimens from 325 of 731 patients in the trial; 197 samples were analyzed for EGFR mutations; and 221 samples were analyzed for the number of EGFR genes. In univariate analyses, survival was longer in the erlotinib group than in the placebo

2005 NEJM

1111. Erlotinib in previously treated non-small-cell lung cancer. (PubMed)

Erlotinib in previously treated non-small-cell lung cancer. 16014882 2005 07 14 2005 07 20 2015 11 19 1533-4406 353 2 2005 Jul 14 The New England journal of medicine N. Engl. J. Med. Erlotinib in previously treated non-small-cell lung cancer. 123-32 We conducted a randomized, placebo-controlled, double-blind trial to determine whether the epidermal growth factor receptor inhibitor erlotinib prolongs survival in non-small-cell lung cancer after the failure of first-line or second-line (...) chemotherapy. Patients with stage IIIB or IV non-small-cell lung cancer, with performance status from 0 to 3, were eligible if they had received one or two prior chemotherapy regimens. The patients were stratified according to center, performance status, response to prior chemotherapy, number of prior regimens, and prior platinum-based therapy and were randomly assigned in a 2:1 ratio to receive oral erlotinib, at a dose of 150 mg daily, or placebo. The median age of the 731 patients who underwent

2005 NEJM

1112. Erlotinib for the management of advanced lung cancer

Erlotinib for the management of advanced lung cancer Erlotinib for the management of advanced lung cancer Erlotinib for the management of advanced lung cancer Augustovski F, Pichon Riviere A, Alcaraz A, Bardach A, Ferrante D, Garcia Marti S, Glujovsky D, Lopez A, Regueiro A Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Augustovski F (...) , Pichon Riviere A, Alcaraz A, Bardach A, Ferrante D, Garcia Marti S, Glujovsky D, Lopez A, Regueiro A. Erlotinib for the management of advanced lung cancer. Ciudad de Buenos Aires: Institute for Clinical Effectiveness and Health Policy (IECS) 2005 Authors' objectives This report is intended to assess the efficacy of Erlotinib for the management of advanced non-small-cell lung carcinoma (NSCLC) and to determine its validated indications. Authors' conclusions Erlotinib has proved to increase survival

2005 Health Technology Assessment (HTA) Database.

1113. Bevacizumab (Avastin) for non-small cell lung cancer (nsclc) - horizon scanning review

Bevacizumab (Avastin) for non-small cell lung cancer (nsclc) - horizon scanning review Bevacizumab (Avastin) for non-small cell lung cancer (nsclc) - horizon scanning review Bevacizumab (Avastin) for non-small cell lung cancer (nsclc) - horizon scanning review NHSC Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation NHSC. Bevacizumab (Avastin (...) ) for non-small cell lung cancer (nsclc) - horizon scanning review. Birmingham: National Horizon Scanning Centre (NHSC). 2005 Authors' objectives This study aims to summarise the currently available evidence on Bevacizumab (Avastin) for non-small cell lung cancer (nsclc). Authors' conclusions Bevacizumab (Avastin) is a humanised vascular endothelial growth factor (VEGF) antibody that is currently in phase III clinical trials for the first-line treatment of advanced nonsquamous, non-small cell lung

2005 Health Technology Assessment (HTA) Database.

1114. Relative efficacy of oral cancer therapy for Medicare beneficiaries versus currently covered therapy: part 1, gefitinib and erlotinib for non-small cell lung cancer

Relative efficacy of oral cancer therapy for Medicare beneficiaries versus currently covered therapy: part 1, gefitinib and erlotinib for non-small cell lung cancer Relative efficacy of oral cancer therapy for Medicare beneficiaries versus currently covered therapy: part 1, gefitinib and erlotinib for non-small cell lung cancer Relative efficacy of oral cancer therapy for Medicare beneficiaries versus currently covered therapy: part 1, gefitinib and erlotinib for non-small cell lung cancer (...) Kelley MJ, McCrory DC Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Kelley MJ, McCrory DC. Relative efficacy of oral cancer therapy for Medicare beneficiaries versus currently covered therapy: part 1, gefitinib and erlotinib for non-small cell lung cancer. Rockville: Agency for Healthcare Research and Quality (AHRQ). Technology Assessment

2005 Health Technology Assessment (HTA) Database.

1115. Gefitinib for advanced lung cancer treatment

Gefitinib for advanced lung cancer treatment Gefitinib for advanced lung cancer treatment Gefitinib for advanced lung cancer treatment Augustovski F, Pichon Riviere A, Alcaraz A, Bardach A, Ferrante D, Garcia Marti S, Glujovsky D, Lopez A, Regueiro A Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Augustovski F, Pichon Riviere A, Alcaraz (...) A, Bardach A, Ferrante D, Garcia Marti S, Glujovsky D, Lopez A, Regueiro A. Gefitinib for advanced lung cancer treatment. Ciudad de Buenos Aires: Institute for Clinical Effectiveness and Health Policy (IECS) 2005 Authors' objectives This report is intended to assess the efficacy of Gefitinib for the treatment non-small-cell Lung carcinoma (NSCLC) and to determine the validated indications for its use. Authors' conclusions The development of epidermal growth factor receptor (EGFR) selective tyrosine

2005 Health Technology Assessment (HTA) Database.

1116. Lung cancer: the diagnosis and treatment of lung cancer

Lung cancer: the diagnosis and treatment of lung cancer Lung cancer: the diagnosis and treatment of lung cancer Lung cancer: the diagnosis and treatment of lung cancer National Institute for Clinical Excellence Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA database. Citation National Institute for Clinical Excellence. Lung cancer: the diagnosis and treatment of lung cancer (...) . London: National Institute for Clinical Excellence (NICE) 2005: 41 Authors' objectives This report provides guidelines on the diagnosis and treatment of lung cancer. Project page URL Indexing Status Subject indexing assigned by CRD MeSH Lung Neoplasms /diagnosis /drug therapy /radiotherapy Language Published English Country of organisation England Address for correspondence MidCity Place, 71 High Holborn, London WC1V 6NA, UK Tel: +44 020 7067 5800 Fax: +44 020 7067 5801 Email: nice@nice.nhs.uk

2005 Health Technology Assessment (HTA) Database.

1117. Positron emission tomography with selected mediastinoscopy compared to routine mediastinoscopy offers cost and clinical outcome benefits for pre-operative staging of non-small cell lung cancer

Positron emission tomography with selected mediastinoscopy compared to routine mediastinoscopy offers cost and clinical outcome benefits for pre-operative staging of non-small cell lung cancer Positron emission tomography with selected mediastinoscopy compared to routine mediastinoscopy offers cost and clinical outcome benefits for pre-operative staging of non-small cell lung cancer Positron emission tomography with selected mediastinoscopy compared to routine mediastinoscopy offers cost (...) and clinical outcome benefits for pre-operative staging of non-small cell lung cancer Yap K K, Yap K S, Byrne A J, Berlangieri S U, Poon A, Mitchell P, Knight S R, Clarke P C, Harris A, Tauro A, Rowe C C, Scott A M Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions

2005 NHS Economic Evaluation Database.

1118. Cost-effectiveness of positron emission tomography for the management of potentially operable non-small cell lung cancer in Quebec

Cost-effectiveness of positron emission tomography for the management of potentially operable non-small cell lung cancer in Quebec Cost-effectiveness of positron emission tomography for the management of potentially operable non-small cell lung cancer in Quebec Cost-effectiveness of positron emission tomography for the management of potentially operable non-small cell lung cancer in Quebec Nguyen V H, Peloquin S, Lacasse Y Record Status This is a critical abstract of an economic evaluation (...) that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology The use of computed tomography (CT) with positron emission tomography (PET) for the management of potentially operable non-small-cell lung cancer (NSCLC). In this intervention, all patients were first evaluated by CT. The use of PET was limited

2005 NHS Economic Evaluation Database.

1119. Economics evaluation of three two-drug chemotherapy regimens in advanced non-small-cell lung cancer

Economics evaluation of three two-drug chemotherapy regimens in advanced non-small-cell lung cancer Economics evaluation of three two-drug chemotherapy regimens in advanced non-small-cell lung cancer Economics evaluation of three two-drug chemotherapy regimens in advanced non-small-cell lung cancer Neymark N, Lianes P, Smit E F, van Meerbeeck J P Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief (...) summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology Three two-drug chemotherapy regimens for patients with advanced non-small-cell lung cancer (NSCLC) were examined: cisplatin-paclitaxel (CIS-PAC) consisted of 175 mg/m2 PAC on day 1 followed by 80 mg/m2 CIS on day 1; cisplatin-gemcitabine (CIS-GEM) consisted of 1,250 mg/m2 GEM on days 1 and day 8 and 80 mg/m2 CIS on day 1 after GEM

2005 NHS Economic Evaluation Database.

1120. Cost-effectiveness analysis of screening for lung cancer with low dose spiral CT (computed tomography) in the Australian setting

Cost-effectiveness analysis of screening for lung cancer with low dose spiral CT (computed tomography) in the Australian setting Cost-effectiveness analysis of screening for lung cancer with low dose spiral CT (computed tomography) in the Australian setting Cost-effectiveness analysis of screening for lung cancer with low dose spiral CT (computed tomography) in the Australian setting Manser R, Dalton A, Carter R, Byrnes G, Elwood M, Campbell D A Record Status This is a critical abstract (...) of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology The use of annual spiral computed tomography (CT) for the screening of lung cancer (LC) over a 5-year interval. Individuals were referred for screening by local medical officers. Suspicious lesions were referred to an appropriate

2005 NHS Economic Evaluation Database.